⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski Si-Qi Liu Lauren M. Zasadil Joseph L. Benci Patrick C. Gedeon Kendall J. Condon Suhasini Joshi Shana Posy Patrick Carlson Alison Maier Jiao Shen Rakeeb Kureshi Yuka Amako Tai Wang Ryan L. Powles Yanyun Li Tho Lai Igor Katsyv Hongchen Qiu Huilin Qi Jessica Wong Dandan Zhao Dana Banas Joelle M. Onorato Gregory Locke Xueer Chen Wen‐Chi Chou Erica Cook Abigail E. Witt Christopher M. Barbieri Hong Zhang Jonathan B. Olsen Alba Font‐Tello Eugene Drokhlyansky Denise C. Grünenfelder Louis Chupak Tyler A. Longmire Jon C. Jones Travis J. Hollmann David Kugler John N. Feder Raphael Bueno John C. Wain Pallavur Sivakumar Yu Liu Stephanie K. Dougan Cloud P. Paweletz David A. Barbie Emma Lees

View Full Paper

Ask AI

Bookmark

Share

Key Points

BMS-986408 significantly improves T cell activation and function in various assays.
Inhibition of DGKα and DGKζ leads to enhanced immune responses against tumors.
Assessment involved T cell functional assays to evaluate direct immunotherapeutic effects.
This research highlights the promise of combined therapies in cancer treatment.

Implication

Dual DGK inhibitor BMS-986408 enhances T cell function, suggesting potential for PD-1 and CAR T-cell immunotherapies.

Abstract

Fig. S1. BMS-986408 DGK family selectivity and activity and in T cell functional assays.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wichroski et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f565 https://doi.org/10.1158/2326-6066.30029431

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
2Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
3Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
4Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
5Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025

More related papers

Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-9864082025
Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual Inhibitor2026